UNSPSC 51392806: Imazodan hydrochloride

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H12N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5EP74J9Q34, chemically known as 4,5-dihydro-6-(p-imidazol-1-ylphenyl)-3(2h)-pyridazinone monohydrochloride but more generally known as imazodan hydrochloride, which bears US NIH Compound Identifier 55917. Most nations, for tariff and trade purposes, schedule imazodan hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, IMAZODAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Imazodan hydrochloride bears US NLM identifiers UMLS ID C0956497 and NCI Concept Code C72811. SMILES: C1CC(CCC1C2=NNC(=O)CC2)N3CCNC3.CL.

UNSPSC 51392806 Imazodan hydrochloride is a Commodity code that shows minimal recent state and local procurement activity directly aligned with its nominal scope. The two most recent opportunities tagged to this code diverge significantly from the pharmaceutical active ingredient the code names: Seminole County, Florida's IFB60459723LAS solicits Naloxone and Safe Drug Deactivation Systems (posted June 30, 2026, response due July 26, 2023), and the Texas Health and Human Services Commission's RFI HHS0017013 seeks vendor capabilities for a Direct-to-Manufacturer Prescriptions program under a Therapeutic Pharmacy Initiative (posted April 3, 2026). Neither opportunity involves procurement of imazodan hydrochloride itself. The mismatch suggests either inconsistent UNSPSC tagging at the issuing bodies or that state and local governments are not currently using this code to buy the specific active ingredient it describes.

The geographic spread of recent activity is limited to Florida and Texas, with no pattern of repeat activity under this code visible in the source. The Seminole County opportunity is an IFB for annual Naloxone and drug deactivation system purchases with quarterly deliveries to a community health building, while the Texas HHS RFI is an exploratory market-research phase seeking information on direct-to-manufacturer prescription programs rather than a competitive procurement with a defined response deadline or award value. Given the absence of relevant recent opportunities and the tagging mismatches, this code appears inactive for state and local procurement purposes at present, warranting either verification of the correct UNSPSC classification or continued monitoring if actual imazodan hydrochloride solicitations emerge from health departments, correctional systems, or emergency medical services in other jurisdictions.